cyc 202 has been researched along with sch772984 in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (sch772984) | Trials (sch772984) | Recent Studies (post-2010) (sch772984) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 52 | 0 | 51 |
| Protein | Taxonomy | cyc 202 (IC50) | sch772984 (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 0.0084 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.0052 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.009 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, C; Gao, L; Luo, X; Yan, J; Zhao, C; Zhao, J; Zhao, W; Zhu, X | 1 |
1 other study(ies) available for cyc 202 and sch772984
| Article | Year |
|---|---|
Cdk5 is required for the neuroprotective effect of transforming growth factor-β1 against cerebral ischemia-reperfusion.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Ischemia; Cell Differentiation; Cell Proliferation; Cyclin-Dependent Kinase 5; Indazoles; MAP Kinase Signaling System; Neurites; Neuroprotective Agents; PC12 Cells; Piperazines; Protein Kinase Inhibitors; Purines; Rats; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Roscovitine; Transforming Growth Factor beta1 | 2017 |